ReviewJournal of nanobiotechnology2022
Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer.
Review in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Magnetic field-guided enhancement of nanoparticle uptake and hyperthermia efficacy in 3D tumour models.Nanoscale advances · 2026Article
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook.Molecules (Basel, Switzerland) · 2026Review
- Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability.Journal of materials science. Materials in medicine · 2026Review
- Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Integrated single-cell and bulk tissue analyses reveal distinct macrophage subtypes and a candidate prognostic signature in colorectal cancer: implications for tumor immune characterization.Frontiers in immunology · 2026Article
- Advanced hydrogel material for colorectal cancer treatment.Drug delivery · 2025Review
- Electrochemical Tracking of Macrophage Migration Inhibitory Factor: A Leap Toward Precision Colorectal Cancer Diagnosis and Prognosis.Biosensors · 2025Article
- Transferrin receptor 1-targeted polymersomes therapy for colorectal cancer.Materials today. Bio · 2025Article
- tsRNA-08614 inhibits glycolysis and histone lactylation by ALDH1A3 to confer oxaliplatin sensitivity in colorectal cancer.Translational oncology · 2025Article
- ROS/Enzyme Dual-Responsive Drug Delivery System for Targeted Colorectal Cancer Therapy: Synergistic Chemotherapy, Anti-Inflammatory, and Gut Microbiota Modulation.Pharmaceutics · 2025Article
- The Effect of the Ethanolic Extracts fromInternational journal of molecular sciences · 2025Article
- Long noncoding RNAWorld journal of gastrointestinal oncology · 2025Article
- Advances in research on the intestinal microbiota in the mechanism and prevention of colorectal cancer (Review).Molecular medicine reports · 2025Review
- CD44 Variant Expression in Follicular Cell-Derived Thyroid Cancers: Implications for Overcoming Multidrug Resistance.Molecules (Basel, Switzerland) · 2025Review
- NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer.World journal of gastroenterology · 2025Article
- An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Copper-based metal-organic frameworks for antitumor application.Journal of nanobiotechnology · 2025Review
- Nano-Radiopharmaceuticals in Colon Cancer: Current Applications, Challenges, and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer is considered one of the major malignancies that threaten the lives and health of people around the world. Patients with CRC are prone to post-operative local recurrence or metastasis, and some patients are advanced at the time of diagnosis and have no chance for complete surgical resection. These factors make chemotherapy an indispensable and important tool in treating CRC. However, the complex composition of the tumor microenvironment and the interaction of cellular and interstitial components constitute a tumor tissue with high cell density, dense extracellular matrix, and high osmotic pressure, inevitably preventing chemotherapeutic drugs from entering and acting on tumor cells. As a result, a novel drug carrier system with targeted nanoparticles has been applied to tumor therapy. It can change the physicochemical properties of drugs, facilitate the crossing of drug molecules through physiological and pathological tissue barriers, and increase the local concentration of nanomedicines at lesion sites. In addition to improving drug efficacy, targeted nanoparticles also reduce side effects, enabling safer and more effective disease diagnosis and treatment and improving bioavailability. In this review, we discuss the mechanisms by which infiltrating cells and other stromal components of the tumor microenvironment comprise barriers to chemotherapy in colorectal cancer. The research and application of targeted nanoparticles in CRC treatment are also classified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.